Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers

Journal of Clinical Microbiology

Volumn 49, Issue 1, 2011, Pages 281-291

  Stressmann, Franziska A ^a   Rogers, Geraint B ^a   Klem, Erich R ^b   Lilley, Andrew K ^a   Donaldson, Scott H ^b   Daniels, Thomas W ^c   Carroll, Mary P ^c   Patel, Nilesh ^a   Forbes, Benjamin ^a   Boucher, Richard C ^b   Wolfgang, Matthew C ^b   Bruce, Kenneth D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; COTRIMOXAZOLE; DORNASE ALFA; ERYTHROMYCIN; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; ITRACONAZOLE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PIPERACILLIN; RNA 16S; SALBUTAMOL; TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ACTINOMYCES; ACTINOMYCES ODONTOLYTICUS; ADULT; ARTICLE; BACTERIAL STRAIN; BIOGEOGRAPHY; BREVUNDIMONAS DIMINUTA; CAPNOCYTOPHAGA; CAPNOCYTOPHAGA GINGIVALIS; CAPNOCYTOPHAGA SPUTIGENA; CLINICAL ARTICLE; CLUSTER ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROL GROUP; CONTROLLED STUDY; CROSS INFECTION; CYSTIC FIBROSIS; DIALISTER INVISUS; FEMALE; FORCED EXPIRATORY VOLUME; FUSOBACTERIUM; FUSOBACTERIUM PERIODONTICUM; GENE SEQUENCE; GENETIC VARIABILITY; GEOGRAPHICAL VARIATION (SPECIES); GRANULICATELLA ADIACENS; HUMAN; LEPTOTRICHIA; LEPTOTRICHIA SHAHII; LUNG CYSTIC FIBROSIS; LYSOBACTER; LYSOBACTER YANGYEONGENSIS; MALE; MICROBIAL COMMUNITY; MOLECULAR CLONING; NEISSERIA; NEISSERIA SUBFLAVA; NUCLEOTIDE SEQUENCE; ORIBACTERIUM SINUS; PARVIMONAS MICRA; PHENYLOBACTERIUM KOREENSE; POLYMERASE CHAIN REACTION; PORPHYROMONAS; PORPHYROMONAS CATONIAE; PREVOTELLA; PREVOTELLA HISTICOLA; PREVOTELLA LOESCHEII; PREVOTELLA MELANINOGENICA; PREVOTELLA NANCEIENSIS; PREVOTELLA PALLENS; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PLECOGLOSSICIDA; RALSTONIA PICKETTII; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; ROTHIA MUCILAGINOSA; SEQUENCE ANALYSIS; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS INTERMEDIUS; STREPTOCOCCUS MITIS; STREPTOCOCCUS PARASANGUINIS; UNITED KINGDOM; UNITED STATES; VEILLONELLA PARVULA;

ADOLESCENT; ADULT; BACTERIA; BIODIVERSITY; CLUSTER ANALYSIS; CYSTIC FIBROSIS; DNA, BACTERIAL; DNA, RIBOSOMAL; FEMALE; GREAT BRITAIN; HUMANS; LUNG; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, DNA; UNITED STATES; YOUNG ADULT;

BACTERIA (MICROORGANISMS);

EID: 78650915627     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01650-10     Document Type: Article

References (39)

1. Balfour-Lynn, I. A., and J. S. Elborn. 2007. Respiratory disease: infection, p. 137-158. In M. Hodson, D. Geddes, and A. Bush (ed.), Cystic Fibrosis, 3rd ed. Hodder Arnold, London, United Kingdom.
2. Bilton, D. 2008. Cystic fibrosis. Medicine 36:273-278.
3. Bittar, F., H. Richet, J. C. Dubus, M. Reynaud-Gaubert, N. Stremler, J. Sarles, D. Raoult, and J. M. Rolain. 2008. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 3:e2908.
4. Cho, J.-C., and J. M. Tiedje. 2000. Biogeography and degree of endemicity of fluorescent Pseudomonas strains in soil. Appl. Environ. Microbiol. 66:5448-5456.
5. Corey, M., F. J. McLaughlin, M. Williams, and H. Levison. 1988. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J. Clin. Epidemiol. 41:583-591.
6. Cystic Fibrosis Trust. 2009. Antibiotic treatment for Cystic Fibrosis-Report of the UK Cystic Fibrosis Trust Antibiotic Working Group, 3rd ed., Cystic Fibrosis Trust, Kent, United Kingdom.
7. Davies, J. C., E. W. Alton, and A. Bush. 2007. Cystic fibrosis. BMJ 335:1255-1259.
8. de Wit, R., and T. Bouvier. 2006. "Everything is everywhere, but, the environment selects"; what did Baas Becking and Beijerinck really say? Environ. Microbiol. 8:755-758.
9. Dodge, J. A., P. A. Lewis, M. Stanton, and J. Wilsher. 2007. Cystic Fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29:522-526.
10. Flume, P. A., P. J. Mogayzel, Jr., K. A. Robinson, C. H. Goss, R. L. Rosenblatt, R. J. Kuhn, B. C. Marshall, and the Clinical Practice Guidelines for Pulmonary Therapies Committee. 2009. Cystic Fibrosis pulmonary guidelines-treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 180:802-808.
11. Frederiksen, B., S. Lanng, C. Koch, and N. Hoiby. 1996. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr. Pulmonol. 21:153-158.
12. Fierer, N., and R. B. Jackson. 2006. The diversity and biogeography of soil bacterial communities. Proc. Natl. Acad. Sci. U. S. A. 103:626-631.
13. Gordon, D. M., and F. FitzGibbon. 1999. The distribution of enteric bacteria from Australian mammals: host and geographical effects. Microbiology 145:2663-2671.
14. Goss, C. H., and M. Rosenfeld. 2004. Update on cystic fibrosis epidemiology. Curr. Opin. Pulm. Med. 10:510-514.
15. Harris, J. K., M. A. De Groote, S. D. Sagel, E. T. Zemanick, R. Kapsner, C. Penvari, H. Kaess, R. R. Deterding, F. J. Accurso, and N. R. Pace. 2007. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 104:20529-20533.
16. Health Protection Agency. 2008. British standard operating procedure 57, national standard method-investigation of bronchoalveolar lavage sputum and associated specimens. BSOP 57i2. Health Protection Agency, London, United Kingdom.
17. Hodson, M. E., N. J. Simmonds, W. J. Warwick, E. Tullis, C. Castellani, B. Assael, J. A. Dodge, M. Corey, and International Study of Aging in Cystic Fibrosis. 2008. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J. Cyst. Fibros. 7:537-542.
18. Hoiby, H. N. 1982. Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr. Scand. Suppl. 301:33-54.
19. Horner-Devine, M. C., M. Lage, J. B. Huges, and B. J. M. Bohannan. 2004. A taxa-area relationship for bacteria. Nature 432:750-753.
20. Hutchison, M. L., and J. R. W. Govan. 1999. Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect. 1:1005-1014.
21. Johansen, H. K., T. A. Kovesi, C. Koch, M. Corey, N. Høiby, and H. Levison. 1998. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr. Pulmonol. 26:89-96.
22. Karpati, F., and J. Jonasson. 1996. Polymerase chain reaction for the detection of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia in sputum patients with cystic fibrosis. Mol. Cell Probes 10:397-403.
23. Littlewood, J. M. 2005. European cystic fibrosis society consensus on standards-a roadmap to "best care." J. Cyst. Fibros. 4:1-5.
24. Liu, W. T., T. L. Marsh, H. Cheng, and L. J. Forney. 1997. Characterization of microbial diversity by determining terminal restriction fragment length polymorphism of genes encoding 16S rRNA. Appl. Environ. Microbiol. 63:4516-4522.
25. Lyczak, J., C. Cannon, and G. Pier. 2002. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15:194-222.
26. Martiny, J. B., B. J. M. Bohannan, J. H. Brown, R. K. Colwell, J. A. Fuhrman, J. L. Green, M. C. Horner-Devine, M. Kane, J. Adams-Krumins, C. R. Kuske, P. J. Morin, S. Naeem, L. Ovreas, A. L. Reysenbach, V. H. Smith, and J. T. Staley. 2006. Microbial biogeography: putting microorganisms on the map. Nat. Rev. Microbiol. 4:102-112.
27. Roemling, U., A. Kader, D. D. Sriramulu, R. Simm, and G. Kronvall. 2005. Worldwide distribution of Pseudomonas aeruginosa clone C strains in the aquatic environment and cystic fibrosis patients. Environ. Microbiol. 7:1029-1038.
28. Rogers, G. B., C. A. Hart, J. R. Mason, M. Hughs, M. J. Walshaw, and K. D. Bruce. 2003. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 41:3548-3558.
29. Rogers, G. B., M. P. Carroll, D. J. Serisier, P. M. Hockey, G. Jones, and K. D. Bruce. 2004. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 42:5176-5183.
30. Rogers, G. B., M. P. Carroll, D. J. Serisier, P. M. Hockey, G. Jones, V. Kehagia, G. J. Connett, and K. D. Bruce. 2006. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J. Clin. Microbiol. 44:2061-2064.
31. Rogers, G. B., T. W. Daniels, A. Tuck, M. P. Carroll, G. J. Connett, G. J. David, and K. D. Bruce. 2009. Studying bacteria in respiratory specimens by using conventional molecular microbiological approaches. BMC Pulm. Med. 15:9-14.
32. Rogers, G. B., S. Skelton, D. J. Serisier, C. J. van der Gast, and K. D. Bruce. 2010. Determining cystic-fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 48:78-86.
33. Salunkhe, P., C. H. Smart, J. A. Morgan, S. Panagea, M. J. Walshaw, C. A. Hart, R. Geffers, B. Tuemmler, and C. Winstanley. 2005. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J. Bacteriol. 187:4908-4920.
34. Shale, D. J. 1996. Cystic fibrosis. Introduction. Thorax 45:880.
35. Sibley, C. D., H. Rabin, and M. G. Surette. 2006. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol. 1:53-61.
36. Sibley, C. D., M. D. Parkins, H. R. Rabin, K. Duan, J. C. Norgaard, and M. G. Surette. 2008. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A. 105:15070-15075.
37. Tunney, M. M., T. R. Field, T. F. Moriarty, S. Patrick, G. Doering, M. S. Muhlebach, M. C. Wolfgang, R. Boucher, D. F. Gilpin, A. McDowell, and J. S. Elborn. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177:995-1001.
38. Van der Gast, C. J., D. Ager, and A. K. Lilley. 2008. Temporal scaling of bacterial taxa is influenced by both stochastic and deterministic ecological factors. Environ. Microbiol. 10:1411-1418.
39. Yankaskas, J. R., B. C. Marshall, B. Sufian, R. H. Simon, and D. Rodman. 2004. Cystic fibrosis adult care-consensus conference report. Chest 125:1S-39S.